Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Celine Le Bailly De Tilleghem"'
Autor:
Min Huang, Peter A. Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O’Shaughnessy
Publikováno v:
Advances in Therapy. 40:1153-1170
Autor:
Min Huang, Joyce O'Shaughnessy, Amin Haiderali, Wilbur Pan, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Peter A. Fasching
Publikováno v:
European Journal of Cancer. 177:45-52
In the KEYNOTE-355 (KN355) trial, pembrolizumab in combination with chemotherapy demonstrated superior efficacy and manageable safety compared with chemotherapy alone in patients with previously untreated locally recurrent inoperable and metastatic t
Autor:
Min Huang, Peter Fasching, Amin Haiderali, Wilbur Pan, Emma Gray, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O’Shaughnessy
Publikováno v:
Immunotherapy. 14(13)
Objective: This study evaluated the cost–effectiveness of pembrolizumab/chemotherapy combinations for previously untreated metastatic triple-negative breast cancer patients in the USA with PD-L1 combined positive score ≥10. Methods: A partitioned
Autor:
Barbara Knorr, Steven S. Smugar, Yasmine S. Wasfi, Celine Le Bailly De Tilleghem, William D. Hanley, Theodore F. Reiss, César Villarán
Publikováno v:
Respiratory Medicine. 106(1):34-46
Leukotriene B4 (LTB(4)) is a potent inflammatory mediator in asthma, and is increased in more severe asthma. Targeting LTB(4), in addition to cysteinyl leukotrienes, could be beneficial in asthma. This was a randomized, double-blind trial of once-dai
Autor:
N. Gilchrist, José A. Rodríguez Portales, Elizabeth Rosenberg, Bente L. Langdahl, Andrew Denker, Celine Le Bailly De Tilleghem, Carolyn DaSilva, Henry G. Bone, Albert Leung, Neil Binkley, Heinrich Resch, Antonio Lombardi
Publikováno v:
Langdahl, B L, Binkley, N, Bone, H, Gilchrist, N, Resch, H, Rodriguez Portales, J, Denker, A, Lombardi, A, Le Bailly De Tilleghem, C, Dasilva, C, Rosenberg, E & Leung, A 2012, ' Odanacatib in the treatment of postmenopausal women with low bone mineral density : five years of continued therapy in a phase 2 study ', Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol. 27, no. 11, pp. 2251-8 . https://doi.org/10.1002/jbmr.1695
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly expressed by osteoclasts. In this 2-year, phase 2, dose-ranging trial, postmenopausal women with bone mineral density (BMD) T-scores −2.0 to −3.5 at spine or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89f2ac657f98791efb06c9cdb019982
https://pure.au.dk/portal/da/publications/odanacatib-in-the-treatment-of-postmenopausal-women-with-low-bone-mineral-density(595ceba3-c2ef-4e64-9c64-f560bfdbadc9).html
https://pure.au.dk/portal/da/publications/odanacatib-in-the-treatment-of-postmenopausal-women-with-low-bone-mineral-density(595ceba3-c2ef-4e64-9c64-f560bfdbadc9).html
Autor:
Juergen Strehlau, Chun Lam, Celine Le Bailly De Tilleghem, Gilbert W. Gleim, Shahnaz Shahinfar, Nicholas J. A. Webb, Thomas G. Wells
Publikováno v:
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 26(8)
No prospective, randomized, double-blind trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported in adults or children with proteinuria secondary to Alport syndrome.This 12-week, double-blind
Autor:
Joseph Triscari, Rachid Massaad, Christopher Milardo, Paul Kah Hing Ling, Celine Le Bailly De Tilleghem, Mary E. Hanson, Fernando Civeira, Andrei Gheorghe Dan
Publikováno v:
Lipids in Health and Disease
Lipids in Health and Disease, Vol 11, Iss 1, p 18 (2012)
Lipids in Health and Disease, Vol 11, Iss 1, p 18 (2012)
Background A considerable number of patients with severely elevated LDL-C do not achieve recommended treatment targets, despite treatment with statins. Adults at high cardiovascular risk with hypercholesterolemia and LDL-C ≥ 2.59 and ≤ 4.14 mmol/